SEC Form 4 · accession 0001209191-15-051961
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Franc Del Fosse
Officer — General Counsel
Period of report
Jun 10, 2015
Accepted (ET)
Jun 10, 2015 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 10, 2015 | M | 10,000 | $13.27 | A | 10,000 | D | |
| Common StockF1 | Jun 10, 2015 | S | 10,000 | $34.48 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4,F2,F3 | $13.27 | Jun 10, 2015 | M | 10,000 | D | — | May 18, 2024 | Common Stock | 10,000 | 50,000 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.36 to $34.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2This option was previously reported as an option for 30,000 shares at an exercise price of $26.55 per share, but was adjusted to reflect the 2-for-1 forward stock split effected by the Issuer on June 5, 2015.
- F3The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 19, 2018.
- F4On June 5, 2015, the Issuer effected a 2-for-1 forward stock split, resulting in the reporting person's ownership of 30,000 additional options.